Breast Cancer Statistics, 2022
Overview
Authors
Affiliations
This article is the American Cancer Society's update on female breast cancer statistics in the United States, including population-based data on incidence, mortality, survival, and mammography screening. Breast cancer incidence rates have risen in most of the past four decades; during the most recent data years (2010-2019), the rate increased by 0.5% annually, largely driven by localized-stage and hormone receptor-positive disease. In contrast, breast cancer mortality rates have declined steadily since their peak in 1989, albeit at a slower pace in recent years (1.3% annually from 2011 to 2020) than in the previous decade (1.9% annually from 2002 to 2011). In total, the death rate dropped by 43% during 1989-2020, translating to 460,000 fewer breast cancer deaths during that time. The death rate declined similarly for women of all racial/ethnic groups except American Indians/Alaska Natives, among whom the rates were stable. However, despite a lower incidence rate in Black versus White women (127.8 vs. 133.7 per 100,000), the racial disparity in breast cancer mortality remained unwavering, with the death rate 40% higher in Black women overall (27.6 vs. 19.7 deaths per 100,000 in 2016-2020) and two-fold higher among adult women younger than 50 years (12.1 vs. 6.5 deaths per 100,000). Black women have the lowest 5-year relative survival of any racial/ethnic group for every molecular subtype and stage of disease (except stage I), with the largest Black-White gaps in absolute terms for hormone receptor-positive/human epidermal growth factor receptor 2-negative disease (88% vs. 96%), hormone receptor-negative/human epidermal growth factor receptor 2-positive disease (78% vs. 86%), and stage III disease (64% vs. 77%). Progress against breast cancer mortality could be accelerated by mitigating racial disparities through increased access to high-quality screening and treatment via nationwide Medicaid expansion and partnerships between community stakeholders, advocacy organizations, and health systems.
Xie L, Liu Y, Yang Y, Wang J, Zhang Y, Wang T Breast Cancer Res Treat. 2025; .
PMID: 40085414 DOI: 10.1007/s10549-025-07665-y.
Zhang N, Shao X, Xu L, Zhu W, Wang H, Luo R BMC Cancer. 2025; 25(1):465.
PMID: 40082810 PMC: 11907953. DOI: 10.1186/s12885-025-13879-6.
Fuqua R Perspect Behav Sci. 2025; 48(1):83-96.
PMID: 40078357 PMC: 11893918. DOI: 10.1007/s40614-024-00430-4.
Jayasekera J, Wilson O, Wojcik K, Kerr E, Brick R, Berrigan D J Cancer Surviv. 2025; .
PMID: 40074972 DOI: 10.1007/s11764-025-01750-3.
Fan Z, Xu Y, Guo S, Song B BMC Pharmacol Toxicol. 2025; 26(1):56.
PMID: 40069893 PMC: 11895172. DOI: 10.1186/s40360-025-00887-2.